{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T06:40:21Z","timestamp":1695883221233},"reference-count":11,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T00:00:00Z","timestamp":1243209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although some cardiac effects, such as palpitations and tachycardia, occur commonly in healthy people, they have also been shown to be associated with agents used to treat the myeloproliferative disorders. Various strategies exist to prevent and manage cardiac effects and minimise their impact on treatment compliance and persistence. These include pre\u2010therapy cardiac assessment, pharmacological intervention and referral to a cardiologist. Ultimately, treating physicians must use their discretion when deciding which management strategy to use and which cardiac side effects require referral to a cardiologist, but the value of continuous dialogue between specialists should not be ignored. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.911","type":"journal-article","created":{"date-parts":[[2010,7,9]],"date-time":"2010-07-09T13:40:46Z","timestamp":1278682846000},"page":"8-10","source":"Crossref","is-referenced-by-count":0,"title":["Myeloproliferative disorder therapy: assessment and management of adverse events\u2014a cardiologist's perspective"],"prefix":"10.1002","volume":"27","author":[{"given":"Dermot","family":"Kenny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,5,25]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"World Health Organization.Cardiovascular diseases: fact sheet. 2007.http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/Accessed 11 March2009."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg017"},{"key":"e_1_2_1_4_2","unstructured":"Shire Pharmaceuticals Ltd.Xagrid 0.5\u2009mg hard capsule. Summary of Product Characteristics November2008."},{"key":"e_1_2_1_5_2","unstructured":"Roche Products Ltd.Roferon\u2010A pre\u2010filled syringe. Summary of Product Characteristics April2007."},{"issue":"4","key":"e_1_2_1_6_2","first-page":"743","article-title":"Diagnostic approach to palpitations","volume":"71","author":"Abbott AV","year":"2005","journal-title":"Am Fam Physician"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00006"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89451-X"},{"key":"e_1_2_1_9_2","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939434"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565002-00002"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.911","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T03:11:12Z","timestamp":1695784272000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,25]]},"references-count":11,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1002\/hon.911"],"URL":"https:\/\/doi.org\/10.1002\/hon.911","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,25]]}}}